Royalty Pharma Q3 2022: Adjusted Cash Receipts up 2% to $597M; raises FY 2022 guidance to $2,750-2,800M

Royalty Pharma plc

2022-Q3 EPS reported $1.14 revenue$1,671,467,000

Net cash from operating activities $539M (+15% YoY); Adjusted Cash Flow $441M (+26% YoY).
Raised FY 2022 Adjusted Cash Receipts guidance to $2,750-2,800M, including $458M from Pfizer's Biohaven acquisition acceleration.
Announced up to $3.0B YTD capital deployment, including R&D funding collaboration with Merck (MK-8189).
Royalty receipts: Cystic fibrosis franchise $208M (+14%), Trelegy added $43M, Januvia/Janumet down 97% to $1M.
Adjusted EBITDA $548M (+3%); operating costs 8% of Adjusted Cash Receipts.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Royalty Pharma plc updated its the third quarter of 2022 guidance (raised).

Period: the third quarter of 2022
Guidance: raised
Result: reported results

Exact text from the filing

On November 8, 2022, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Royalty Pharma plc filing history →

Source: SEC EDGAR

accession 0001802768-22-000043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.